Revisiting fractionation in prostate carbon ion therapy: first comparative analysis of biologically effective dose using mMKM with diverse parameters.
1/5 보강
[BACKGROUND] Carbon ion radiotherapy (CIRT) for prostate cancer has evolved from conventional regimens [66 Gy(RBE)/20 fractions (66G20), 63 Gy(RBE)/20 fractions (63G20)] toward hypofractionated schedu
APA
Chiou CC, Liu YM, et al. (2026). Revisiting fractionation in prostate carbon ion therapy: first comparative analysis of biologically effective dose using mMKM with diverse parameters.. Radiation oncology (London, England), 21(1), 29. https://doi.org/10.1186/s13014-026-02790-4
MLA
Chiou CC, et al.. "Revisiting fractionation in prostate carbon ion therapy: first comparative analysis of biologically effective dose using mMKM with diverse parameters.." Radiation oncology (London, England), vol. 21, no. 1, 2026, pp. 29.
PMID
41634712 ↗
Abstract 한글 요약
[BACKGROUND] Carbon ion radiotherapy (CIRT) for prostate cancer has evolved from conventional regimens [66 Gy(RBE)/20 fractions (66G20), 63 Gy(RBE)/20 fractions (63G20)] toward hypofractionated schedules [57.6 Gy(RBE)/16 fractions (57.6G16), 51.6 Gy(RBE)/12 fractions (51.6G12), and 40 Gy(RBE)/4 fractions (40G4)]. Whether these are biologically equivalent remains unclear. To our knowledge, this is the first study to systematically evaluate the biological effects of these regimens using the modified microdosimetric kinetic model (mMKM) across diverse parameter settings.
[METHODS] Biologically effective dose (BED) was calculated using four approaches: (1) photon linear-quadratic (LQ) model (2), modified microdosimetric kinetic model (mMKM) with human salivary gland parameters and fixed RBE of 2.41 (3), mMKM3.1, and (4) mMKM with varied domain radius (0.2–0.5 μm) and α/β (1.5–10 Gy). Tumor control probability (TCP) was further estimated based on a reanalysis of the Ion Prostate Irradiation trial.
[RESULTS] Photon LQ analysis suggested near-equivalent BEDs for 63G20, 57.6G16, and 51.6G12 (~ 200 Gy and ~ 130 Gy for α/β = 1.5 and 3 Gy), with 40G4 markedly higher. In contrast, all mMKM-based methods showed progressive BED reductions with hypofractionation versus 63G20 (–16.8% to − 11.3% for 51.6G12; − 30.4% to − 5.2% for 40G4). TCP decreased by 15.5% for 51.6G12 and 28.7% for 40G4. mMKM also yielded higher effective α/β values for CIRT, reflecting reduced fractionation sensitivity.
[CONCLUSIONS] mMKM-based modeling challenges the assumption of dose equivalence in hypofractionated prostate CIRT, suggesting potential underdosing risks. This parameter-sensitive analysis underscores the need for biologically robust models to refine dose prescription and optimize outcomes in particle therapy.
[CLINICAL TRIAL NUMBER] Not applicable.
[SUPPLEMENTARY INFORMATION] The online version contains supplementary material available at 10.1186/s13014-026-02790-4.
[METHODS] Biologically effective dose (BED) was calculated using four approaches: (1) photon linear-quadratic (LQ) model (2), modified microdosimetric kinetic model (mMKM) with human salivary gland parameters and fixed RBE of 2.41 (3), mMKM3.1, and (4) mMKM with varied domain radius (0.2–0.5 μm) and α/β (1.5–10 Gy). Tumor control probability (TCP) was further estimated based on a reanalysis of the Ion Prostate Irradiation trial.
[RESULTS] Photon LQ analysis suggested near-equivalent BEDs for 63G20, 57.6G16, and 51.6G12 (~ 200 Gy and ~ 130 Gy for α/β = 1.5 and 3 Gy), with 40G4 markedly higher. In contrast, all mMKM-based methods showed progressive BED reductions with hypofractionation versus 63G20 (–16.8% to − 11.3% for 51.6G12; − 30.4% to − 5.2% for 40G4). TCP decreased by 15.5% for 51.6G12 and 28.7% for 40G4. mMKM also yielded higher effective α/β values for CIRT, reflecting reduced fractionation sensitivity.
[CONCLUSIONS] mMKM-based modeling challenges the assumption of dose equivalence in hypofractionated prostate CIRT, suggesting potential underdosing risks. This parameter-sensitive analysis underscores the need for biologically robust models to refine dose prescription and optimize outcomes in particle therapy.
[CLINICAL TRIAL NUMBER] Not applicable.
[SUPPLEMENTARY INFORMATION] The online version contains supplementary material available at 10.1186/s13014-026-02790-4.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
같은 제1저자의 인용 많은 논문 (1)
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- Prostate Cancer Care for Men with an Intellectual Disability: A Population-based Cohort Study of Symptoms, Diagnosis, Treatment, and Survival.
- A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results.
- Clinical and Liquid Biomarkers of 20-Year Prostate Cancer Risk in Men Aged 45 to 70 Years.
- Association between polygenic risk scores and cardiovascular events in prostate cancer patients receiving androgen deprivation therapy in Han Chinese.
- Diagnostic accuracy of Ga-PSMA PET/CT versus multiparametric MRI for preoperative pelvic invasion in the patients with prostate cancer.
- Interleukin-11: A pivotal player and potential therapeutic target in prostate cancer.